Top Gap Ups and Downs on Friday: IX, TTWO, EXPE and More
European Equities Traded in the US as American Depositary Receipts Rise Friday
Top Gap Ups and Downs on Thursday: LLY, PH, MCK and More
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Novartis Says FDA Gives Accelerated Approval for Kidney-Disease Treatment
Novartis Receives FDA Accelerated Approval for Fabhalta (Iptacopan), the First and Only Complement Inhibitor for the Reduction of Proteinuria in Primary IgA Nephropathy (IgAN)
Express News | US FDA Approves Novartis' Fabhalta For Reducing Proteinuria In Adults With Primary Immunoglobulin A Nephropathy (IgAN)
New Drugs and Cost Controls Fuel Wave of Pharma Guidance Lifts -- Analysis
Novartis AG (NVS): The Best Organ Transplant and Diagnosis Stock According to Street Analysts?
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Top Gap Ups and Downs on Thursday: META, TM, APD and More
Novartis Sues FDA for Approving Entresto Generic
Swiss stock exchange suspends trading for several hours, the second interruption in 13 months.
The Swiss stock market operator suspended stock trading for several hours on Wednesday due to a technical glitch that prevented the release of price data. This is the longest disruption in the exchange's history and the second to be affected in more than a year. SIX Swiss Exchange said the trading pause began at 10:00 a.m. Zurich time and resumed trading at 2:30 p.m. A spokesperson said the exchange had been unable to publish market data and indices since around 9:10 a.m. The data for the Spanish stock market was also affected for several hours, but trading continued. This interruption was due to the Swiss stock exchange.
Top Gap Ups and Downs on Tuesday: PG, DEO, PYPL and More
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
US FDA Grants Priority Review to Novartis' Chronic Myeloid Leukemia Treatment
Top Gap Ups and Downs on Monday: TSLA, BABA, SNY and More
Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
Novartis Scemblix Granted FDA Priority Review For The Treatment Of Adults With Newly Diagnosed CML